Genmab A/S

Genmab's core cash-generation is durable because its top-line is driven by high-margin royalties/milestone income and/or product revenue rather than low-margin manufacturing — so revenue growth converts to gross profit and cash at very high rates. If true, owners get recurring cash and high margins that fund returns or reinvestment; if false, revenues could fall or margins compress and cash generation would deteriorate.

The business reliably converts reported revenue into operating cash flow, so ongoing operations fund R&D, milestones or capital returns without routine equity dilution. Sustained positive OCF preserves optionality (buybacks, reinvestment, dividends) and reduces funding risk; loss of cash conversion would force dilution or spending cuts.

A large 2025 increase in liabilities reflects material contract liabilities / financing tied to future deliverables; the firm's earnings and equity are levered to successful achievement of those future milestones/deliverables. If the related milestones/deliverables fail, recognized assets/revenue could be reversed or liabilities crystallized, compressing earnings and equity value before top-line erosion appears.

GAAP EPS is materially affected by episodic licensing, milestone recognition or accounting items, so EPS/lump-sum net income swings do not reliably signal underlying recurring business strength. If true, investors should focus on revenue mix and cash flow rather than year-to-year EPS; if false and EPS becomes steady, valuation should re-rate on stable earnings.